[1]Brenner H，Kloor M，Pox CP.Colorectal cancer［J］.Lancet，2014，383(9927)：1490-1502.
[2]Muratore A，Zorzi D，Bouzari H，et al.Asymptomatic colorectal cancer with un-resectable liver metastases：Immediate colorectal resection or up-front systemic chemotherapy［J］?Ann Surg Oncol，2007，14(2)：766-770.
[3]Lee WS，Yun SH，Chun HK，et al.Pulmonary resection for metastases from colorectal cancer：Prognostic factors and survival［J］.Int J Colorectal Dis，2007，22(6)：699-704.
[4]Van Cutsem E，Nordlinger B，Adam R，et al.Towards a pan-European consensus on the treatment of patients with colorectal liver metastases［J］.Eur J Cancer，2006，42(14)：2212-2221.
[5]Yoo PS，Lopez-Soler RI，Longo WE，et al.Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab［J］.Clin Colorectal Cancer，2006，6(3)：202-207.
[6]Bupathi M，Wu C.Biomarkers for immune therapy in colorectal cancer：Mismatch-repair deficiency and others［J］.J Gastrointest Oncol，2016，7(5)：713-720.
[7]Venook AP，Niedzwiecki D，Lenz HJ，et al.CALGB/SWOG 80405：Phase Ⅲ trial of irinotecan/5-FU/leucovorin（FOLFIRI) or oxaliplatin/5-FU/leucovorin（mFOLFOX6) with bevacizumab（BV) or cetuximab（CET) for patients（pts) with KRAS wild-type（wt) untreated metastatic adenocarcinoma of the colon or rectum［J］.Clin Oncol,2014,32：55.
[8]Ansell SM，Lesokhin AM，Borrello I，et al.PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma［J］.N Engl J Med，2015，372(4)：311-319.
[9]Mezache L，Paniccia B，Nyinawabera A，et al.Enhanced expression of PD-L1 in cervical intraepithelial neoplasia and cervical cancers［J］.Mod Pathol，2015，28(12)：1594-1602.
[10]Powles T，Eder JP，Fine GD，et al.MPDL3280A（anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer［J］.Nature，2014，515(7528)：558-562.
[11]Starke A，Lindenmeyer MT，Segerer S，et al.Renal tubular PD-L1（CD274) suppresses alloreactive human T-cell responses［J］.Kidney Int，2010，78(1)：38-47.
[12]Callahan MK，Kluger H，Postow MA，et al.Nivolumab plus ipilimumab in patients with advanced melanoma：Updated survival，response，and safety data in a phase I dose-escalation study［J］.J Clin Oncol，2018，36(4)：391-398.
[13]Venderbosch S，Nagtegaal ID，Maughan TS，et al.Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients：A pooled analysis of the CAIRO，CAIRO2，COIN，and FOCUS studies［J］.Clin Cancer Res，2014，20(20)：5322-5330.
[14]Lipson EJ，Sharfman WH，Drake CG，et al.Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody［J］.Clin Cancer Res，2013，19(2)：462-468.
[15]Goldstein J，Tran B，Ensor J，et al.Multicenter retrospective analysis of metastatic colorectal cancer（CRC) with high-level microsatellite instability（MSI-H)［J］.Ann Oncol，2014，25(5)：1032-1038.
[16]Sclafani F.PD-1 inhibition in metastatic dMMR/MSI-H colorectal cancer［J］.Lancet Oncol，2017，18(9)：1141-1142.
[17]Saeterdal I，Bjrheim J，Lislerud K，et al.Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer［J］.Proc Natl Acad Sci USA，2001，98(23)：13255-13260.
[18]Koopman M，Kortman GA，Mekenkamp L，et al.Deficient mismatch repair system in patients with sporadic advanced colorectal cancer［J］.Br J Cancer，2009，100(2)：266-273.
[19]Gatalica Z，Vranic S，Xiu J，et al.High microsatellite instability（MSI-H) colorectal carcinoma：A brief review of predictive biomarkers in the era of personalized medicine［J］.Fam Cancer，2016，15(3)：405-412.
[20]Llosa NJ，Cruise M，Tam A，et al.The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints［J］.Cancer Discov，2015，5(1)：43-51.
[21]Ogura T，Kakuta M，Yatsuoka T，et al.Clinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations［J］.Oncol Rep，2014，32(1)：50-56.
[22]Klingbiel D，Saridaki Z，Roth AD，et al.Prognosis of stage Ⅱ and Ⅲ colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status：Results of the PETACC-3 trial［J］.Ann Oncol，2015，26(1)：126-132.
[23]Ribic CM，Sargent DJ，Moore MJ，et al.Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer［J］.N Engl J Med，2003，349(3)：247-257.
[24]Goldstein J，Tran B，Ensor J，et al.Multicenter retrospective analysis of metastatic colorectal cancer（CRC) with high-level microsatellite instability（MSI-H)［J］.Ann Oncol，2014，25(5)：1032-1038.
[25]Ishida Y，Agata Y，Shibahara K，et al.Induced expression of PD-1，a novel member of the immunoglobulin gene superfamily，upon programmed cell death［J］.EMBO J，1992，11(11)：3887-3895.
[26]Dong H，Zhu G，Tamada K，et al.B7-H1，a third member of the B7 family，co-stimulates T-cell proliferation and interleukin-10 secretion［J］.Nat Med，1999，5(12)：1365-1369.
[27]Latchman Y，Wood CR，Chernova T，et al.PD-L2 is a second ligand for PD-1 and inhibits T cell activation［J］.Nat Immunol，2001，2(3)：261-268.
[28]Ji M，Liu Y，Li Q，et al.PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation［J］.J Transl Med，2015，13：5.
[29]Francisco LM，Salinas VH，Brown KE，et al.PD-L1 regulates the development，maintenance，and function of induced regulatory T cells［J］.J Exp Med，2009，206(13)：3015-3029.
[30]Le DT，Uram JN，Wang H，et al.PD-1 blockade in tumors with mismatch-repair deficiency［J］.N Engl J Med，2015，372(26)：2509-2520.
[31]Overman MJ，McDermott R，Leach JL，et al.Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer（CheckMate 142)：An open-label，multicentre，phase Ⅱ study［J］.Lancet Oncol，2017，18(9)：1182-1191.
[32]Overman MJ，Lonardi S，Wong KYM，et al.Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer［J］.J Clin Oncol，2018，36(8)：773-779.
[33]Hochster HS，Bendell JC，Cleary JM，et al.Efficacy and safety of atezolizumab（atezo) and bevacizumab（bev) in a phase Ib study of microsatellite instability（MSI)-high metastatic colorectal cancer（mCRC)［J］.J Clin Oncol，2017，35（suppl 4S):673.
[34]Boland PM，Ma WW.Immunotherapy for colorectal cancer［J］.Cancers（Basel),2017,9:50.